Durvalumab adjuvant therapy for treating hepatocellular carcinoma at high risk of recurrence after curative treatment

Durvalumab as an adjuvant therapy is in clinical development for treating hepatocellular carcinoma (HCC), the most common type of liver cancer, where there is a high risk of the cancer returning after curative treatment. It is common that people with HCC are asymptomatic (do not show symptoms related to the cancer). There is increased risk of developing HCC if you have underlying liver disease (e.g., hepatitis B/C or non-alcoholic fatty liver disease), or cirrhosis (scarring of the liver). There is an unmet need in this setting as no effective treatments have been identified for HCC that is at risk of returning after surgery.